Elite Pharmaceuticals (ELTP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Elite Pharmaceuticals

OTC Markets OTCQB•Healthcare•Drug Manufacturers - Specialty & Generic

$0.260.00(0.00%)After hours

Market Cap

$269.31M

P/E

4.8x

P/S

1.9x

P/B

2.6x

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

How this company scores

ExcellentMetricSide Score: 81/100

Strongest: Balance Sheet & Red Flags (25/25); weakest: Cash & Earnings Quality (10/25).

Profitability22/25

Growth24/25

Balance Sheet & Red Flags25/25

Cash & Earnings Quality10/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 4.8x5y range 4.2x – 52.3x

Currently below its 16-quarter median.

P/S · 1.9x5y range 0.9x – 8.5x

Currently near its 20-quarter median.

P/B · 2.6x5y range 1.0x – 16.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Watch

Operating margins declined 13.5% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.0x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $269.31M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $141.01M
Q. Revenue: $32.36M
TTM EBITDA: $35.99M
TTM Op. Income: $34.94M
Q. Op. Income: $7.53M
TTM Net Income: $56.67M
Q. Net Income: $5.91M
EPS: $0.01
Shares Out.: $1.08B

$141.01M in TTM revenue grew 33.7% YoY, reaching $32.36M last quarter. TTM EBITDA of $35.99M and TTM operating income of $34.94M show growth is flowing through to the bottom line. TTM net income of $56.67M means revenue is converting into profit. Over the past year, TTM revenue is up 34% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 41.7%
EBITDA Margin: 24.1%
Op. Margin: 23.3%
Net Margin: 18.3%

Op. margin of 23.3% is down 30.7% YoY — costs are rising relative to revenue. Net margin at 18.3% and gross margin of 41.7% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 4.8x
P/S Ratio: 1.9x
P/B Ratio: 2.6x

At 4.8x P/E, the stock trades below typical market levels. P/S of 1.9x and P/B of 2.6x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $139.67M
Cash: $39.42M
Long-Term Debt: $655,103
Book Value: $104.83M
D/E Ratio: 0.0
Debt/EBITDA: 0.1

With $139.67M in assets and $655,103 in long-term debt, D/E is 0.0and book value is $104.83M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 4 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $10.07M
TTM Free Cash Flow: $17.53M
FCF Margin: 12.4%
FCF / Net Income: 0.3

TTM FCF of $17.53M on $10.07M in operating cash flow. The FCF / Net Income ratio of 0.3x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 3% — a weakening trend.